Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 6/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555415 | 0.94 | EPHX2 (0.57) | EPHX2DRD2HRH2HRH1 | |
| SCHEMBL14453585 | 0.86 | KCNA5 (0.62) | GPR4DRD3EPHX2DRD2KCNA5 | |
| SCHEMBL19479118 | 0.86 | DRD3 (0.70) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL20423457 | 0.86 | DRD3 (0.55) | GPR4DRD3EPHX2DRD2GPR119 | |
| SCHEMBL23301374 | 0.85 | DRD3 (0.54) | GPR4DRD3EPHX2DRD2GPR119 | |
| SCHEMBL6034847 | 0.85 | HRH2 (0.61) | GPR4DRD3EPHX2DRD2GPR119 | |
| SCHEMBL1730771 | 0.85 | HRH2 (0.58) | GPR4DRD3EPHX2DRD2GPR119 | |
| SCHEMBL14453658 | 0.85 | DRD3 (0.54) | GPR4DRD3EPHX2DRD2GPR119 | |
| SCHEMBL18135536 | 0.85 | KCNA5 (0.64) | DRD3EPHX2DRD2KCNA5LTA4H | |
| SCHEMBL25747712 | 0.84 | GPR4 (0.56) | GPR4DRD3EPHX2DRD2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109004-A1 | NAPHTHYLUREA-PIPERAZINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 河南省锐达医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | GPR4 1688/4885DRD3 4379/4885EPHX2 1520/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | GPR4 1688/4885DRD3 4379/4885EPHX2 1520/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | GPR4 1688/4885DRD3 4379/4885EPHX2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.